US-based TearScience has released LipiScan, a dedicated high-definition (HD) imager to test meibomian glands for treatment of meibomian gland dysfunction (MGD).

Claimed to be the first of its kind, LipiScan is based on patented dynamic meibomian imaging (DMI) technology to generate high-definition images of meibomian glands.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MGD accounts being a prevalent chronic, obstructive and progressive disease that affects the tear film, visual performance and ocular comfort.

"We saw the need for a technology to make assessment of meibomian glands routine."

TearScience president and CEO Joseph Boorady said: "Amid growing recognition of MGD as a core root cause of fluctuating vision and discomfort, we saw the need for a technology to make assessment of meibomian glands routine.

"We are proud to transform care and lead innovation for MGD. LipiScan allows ECPs to evaluate meibomian gland structure in all patients.

See Also:

"Because it is largely caused by modern lifestyles, many patients are at risk for MGD including surgical, contact lens and dry eye patients."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new LipiScan dynamic meibomian imager (DMI) is an ophthalmic imaging device, which is used by physicians in adult patients to generate, archive and modify distinguishing images of meibomian gland structure.

The company noted that it will market LipiScan in an affordable price to enable the physicians to evaluate meibomian gland structure during routine workups in any practice setting.